<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029872</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00079147</org_study_id>
    <nct_id>NCT02029872</nct_id>
  </id_info>
  <brief_title>Stop Community MRSA Colonization Among Patients</brief_title>
  <acronym>SUSTAIN</acronym>
  <official_title>Stop Community MRSA Colonization Among Patients (SUSTAIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Wood Johnson Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to learn more about an approach to remove Methicillin resistant
      Staphylococcus aureus (MRSA) in patients who are carriers of the bacteria in outpatient
      settings and among their household members and sexual partners.

      MRSA is a type of bacteria or germ that can cause bad infections of the skin that can make
      people very sick. The bacteria have been seen in a high number of persons in the Baltimore
      area and in hospitals throughout the country. MRSA can be spread from person to person,
      particularly in homes and among family members and sexual partners.

      There are three things the investigators hope to learn from this research study:

      First, the investigators want to find a way to prevent MRSA infections in outpatient
      settings. By asking questions, the investigators want to look at the things that may increase
      the risk of having this type of bacteria in you and your family members.

      Second, the investigators have soaps and oral rinses (Chlorhexidine) and medications
      (antibiotics; Mupirocin ointment) that have been shown to be effective at removing MRSA. The
      investigators want to determine if these antibiotics and soaps are best used for everyone in
      the household or only the individual with known MRSA.

      Third, as the investigators, we want to learn more about the bacteria by looking at it on the
      inside. The investigators will do laboratory tests on samples we collect, to learn how MRSA
      bacteria grow, reproduce and how it develops to behave differently than other types of MRSA
      bacteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methicillin resistant Staphylococcus aureus (MRSA) kills more patients in the United States
      (U.S.) than Acquired Immunodeficiency Syndrome (AIDS). Further, persons living with Human
      Immunodeficiency Virus (HIV) experience MRSA infection at significantly higher rates than the
      general population (12.3/ 1000 person years compared to 1 to 2/1000 person years) and MRSA
      remains a substantial reason for hospital admission among this patient population.
      Colonization with Staphylococcus aureus is a major risk factor for infection in persons
      living with HIV and AIDS (PLWHA) and eradication of MRSA colonization reduces the occurrence
      of subsequent infection in patients. Household contacts with MRSA colonization increase
      failure rates of decolonization. The clinical practice guidelines for MRSA management from
      the Infectious Diseases Society of America (IDSA) recommend providing decolonization to
      persons with repeated skin and soft tissue infections as well as their household contacts;
      however, the guidelines report that evidence is limited in support of this recommendation.
      Additionally, these recommendations do not include sexual partners outside the home and there
      is mounting evidence of MRSA transmission between sexual partners and sexual networks.
      Strategies that reduce the spread of MRSA among people living with HIV/AIDS (PLWHA) are
      vitally needed to reduce this disparity.

      To assess colonization prevalence among PLWHA, investigators conducted an epidemiologic
      evaluation of MRSA among persons within the Johns Hopkins University AIDS Service (JHUAS).
      The study included 500 subjects (65.8 % male) along with the sexual partners of 35 subjects.
      The MRSA colonization prevalence was 16.8% among subjects and 37% (17/35) in their sexual
      partners (unpublished data). These findings demonstrate an exceptional difference in
      colonization prevalence in PLWHA compared to the US population and supports the need for
      further research to understand decolonization regimens that evaluate outcomes for individual
      decolonization only compared to the inclusion household and/or sexual partner interventions.
      We propose a randomized controlled trial (RCT) among 100 PLWHA (50 per arm) within the JHUAS
      to evaluate an individual versus household/sexual partner decolonization intervention.

      The specific aims of the proposed RCT are:

        1. To compare a MRSA decolonization protocol for the colonized individual (index) versus
           the index plus their household member and/or routine sexual partner(s).

           H0: Index plus household/sexual partner(s) decolonization will be associated with a
           lower occurrence of MRSA colonization at 6 months after completion of decolonization
           protocol.

        2. To estimate the intervention effect size and develop an intervention fidelity assessment
           plan to scale the intervention into a larger multi-city R01 application.

        3. To determine the molecular characteristics and antimicrobial susceptibilities of both
           the clinical and colonizing isolates among index patient as well as household members.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization</measure>
    <time_frame>6 months</time_frame>
    <description>Participants were decolonized with a standard Methicillin-resistant Staphylococcus aureus (MRSA) decolonization protocol and monitored for 6 months. This is the number of participants who screened positive for Methicillin-resistant Staphylococcus aureus (MRSA) 6 months after being decolonized (i.e., recurrent infection)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>MRSA</condition>
  <arm_group>
    <arm_group_label>Individual plus household</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individual alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate soap</intervention_name>
    <description>4% chlorhexidine gluconate (soap)</description>
    <arm_group_label>Individual plus household</arm_group_label>
    <arm_group_label>Individual alone</arm_group_label>
    <other_name>Hibiclens</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine gluconate oral rinse</intervention_name>
    <description>chlorhexidine gluconate oral rinse 0.12%</description>
    <arm_group_label>Individual plus household</arm_group_label>
    <arm_group_label>Individual alone</arm_group_label>
    <other_name>Chlorhexidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin calcium 2 % ointment</intervention_name>
    <description>nasal mupirocin calcium 2% ointment</description>
    <arm_group_label>Individual plus household</arm_group_label>
    <arm_group_label>Individual alone</arm_group_label>
    <other_name>Mupirocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals, 21 years of age and older, of all racial and ethnic groups, receiving
             care within the Johns Hopkins University AIDS Service who have a prior history of MRSA
             colonization are eligible to participate as the index HIV positive subject

          -  have at least two members in the household and/or a sexual partner

          -  subjects must be willing to be randomized to either arm of the study, including
             randomization to household and/or sexual partner evaluation that includes home visits

          -  Sexual partners and/or household members will also be required to provide informed
             consent

          -  Subjects and their contacts must have no documented or reported allergies to any agent
             used in the standardized decolonization regimen

          -  Parental assent will be required for household members less than 7 years of age

        Exclusion Criteria:

          -  individuals who live alone and have no active sexual partners

          -  allergy to any component of decolonization protocol

          -  individuals who are unable to provide written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason E Farley, PhD, MPH, NP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007 Oct 17;298(15):1763-71.</citation>
    <PMID>17940231</PMID>
  </reference>
  <reference>
    <citation>Crum-Cianflone N, Weekes J, Bavaro M. Recurrent community-associated methicillin-resistant Staphylococcus aureus infections among HIV-infected persons: incidence and risk factors. AIDS Patient Care STDS. 2009 Jul;23(7):499-502. doi: 10.1089/apc.2008.0240.</citation>
    <PMID>19530952</PMID>
  </reference>
  <reference>
    <citation>Crum-Cianflone NF, Grandits G, Echols S, Ganesan A, Landrum M, Weintrob A, Barthel R, Agan B; Infectious Disease Clinical Research Program. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr. 2010 Jul;54(3):248-57.</citation>
    <PMID>20658748</PMID>
  </reference>
  <reference>
    <citation>Shet A, Mathema B, Mediavilla JR, Kishii K, Mehandru S, Jeane-Pierre P, Laroche M, Willey BM, Kreiswirth N, Markowitz M, Kreiswirth BN. Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. J Infect Dis. 2009 Jul 1;200(1):88-93. doi: 10.1086/599315.</citation>
    <PMID>19463064</PMID>
  </reference>
  <reference>
    <citation>Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008 Jun;29(6):510-6. doi: 10.1086/588201.</citation>
    <PMID>18510460</PMID>
  </reference>
  <reference>
    <citation>Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, Bonten MJ; MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure. J Antimicrob Chemother. 2011 Oct;66(10):2418-24. doi: 10.1093/jac/dkr250. Epub 2011 Jun 30.</citation>
    <PMID>21719471</PMID>
  </reference>
  <reference>
    <citation>Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4. Erratum in: Clin Infect Dis. 2011 Aug 1;53(3):319.</citation>
    <PMID>21208910</PMID>
  </reference>
  <reference>
    <citation>Crum-Cianflone NF, Shadyab AH, Weintrob A, Hospenthal DR, Lalani T, Collins G, Mask A, Mende K, Brodine SK, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV). Medicine (Baltimore). 2011 Nov;90(6):379-89. doi: 10.1097/MD.0b013e318238dc2c.</citation>
    <PMID>22033452</PMID>
  </reference>
  <reference>
    <citation>Shadyab AH, Crum-Cianflone NF. Methicillin-resistant Staphylococcus aureus (MRSA) infections among HIV-infected persons in the era of highly active antiretroviral therapy: a review of the literature. HIV Med. 2012 Jul;13(6):319-32. doi: 10.1111/j.1468-1293.2011.00978.x. Epub 2012 Jan 25. Review.</citation>
    <PMID>22276696</PMID>
  </reference>
  <reference>
    <citation>Graham PL 3rd, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med. 2006 Mar 7;144(5):318-25.</citation>
    <PMID>16520472</PMID>
  </reference>
  <reference>
    <citation>Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008 Feb 19;148(4):249-57. Epub 2008 Jan 30.</citation>
    <PMID>18283202</PMID>
  </reference>
  <reference>
    <citation>Crum-Cianflone NF, Burgi AA, Hale BR. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS. 2007 Aug;18(8):521-6.</citation>
    <PMID>17686212</PMID>
  </reference>
  <reference>
    <citation>Skiest DJ, Brown K, Cooper TW, Hoffman-Roberts H, Mussa HR, Elliott AC. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect. 2007 May;54(5):427-34. Epub 2006 Oct 27.</citation>
    <PMID>17070598</PMID>
  </reference>
  <reference>
    <citation>Al-Rawahi GN, Schreader AG, Porter SD, Roscoe DL, Gustafson R, Bryce EA. Methicillin-resistant Staphylococcus aureus nasal carriage among injection drug users: six years later. J Clin Microbiol. 2008 Feb;46(2):477-9. Epub 2007 Nov 26.</citation>
    <PMID>18039800</PMID>
  </reference>
  <reference>
    <citation>Huang H, Cohen SH, King JH, Monchaud C, Nguyen H, Flynn NM. Injecting drug use and community-associated methicillin-resistant Staphylococcus aureus infection. Diagn Microbiol Infect Dis. 2008 Apr;60(4):347-50. doi: 10.1016/j.diagmicrobio.2007.11.001. Epub 2008 Feb 21.</citation>
    <PMID>18178362</PMID>
  </reference>
  <reference>
    <citation>Lee NE, Taylor MM, Bancroft E, Ruane PJ, Morgan M, McCoy L, Simon PA. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis. 2005 May 15;40(10):1529-34. Epub 2005 Apr 13. Erratum in: Clin Infect Dis. 2005 Jul 1;41(1):135.</citation>
    <PMID>15844078</PMID>
  </reference>
  <reference>
    <citation>Mathews WC, Caperna JC, Barber RE, Torriani FJ, Miller LG, May S, McCutchan JA. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):155-60.</citation>
    <PMID>16186732</PMID>
  </reference>
  <reference>
    <citation>Drapeau CM, Angeletti C, Festa A, Petrosillo N. Role of previous hospitalization in clinically-significant MRSA infection among HIV-infected inpatients: results of a case-control study. BMC Infect Dis. 2007 Apr 30;7:36.</citation>
    <PMID>17470274</PMID>
  </reference>
  <reference>
    <citation>Fritz SA, Hogan PG, Hayek G, Eisenstein KA, Rodriguez M, Epplin EK, Garbutt J, Fraser VJ. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial. Clin Infect Dis. 2012 Mar;54(6):743-51. doi: 10.1093/cid/cir919. Epub 2011 Dec 23.</citation>
    <PMID>22198793</PMID>
  </reference>
  <reference>
    <citation>Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, Bonten MJ; MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother. 2011 Oct;66(10):2409-17. doi: 10.1093/jac/dkr243. Epub 2011 Jun 30.</citation>
    <PMID>21719473</PMID>
  </reference>
  <reference>
    <citation>Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672-7. doi: 10.1016/j.ijsu.2011.09.004. Epub 2011 Oct 13.</citation>
    <PMID>22019563</PMID>
  </reference>
  <reference>
    <citation>Farley JE, Stamper PD, Ross T, Cai M, Speser S, Carroll KC. Comparison of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) PCR assay to culture by use of BBL CHROMagar MRSA for detection of MRSA in nasal surveillance cultures from an at-risk community population. J Clin Microbiol. 2008 Feb;46(2):743-6. Epub 2007 Dec 5.</citation>
    <PMID>18057129</PMID>
  </reference>
  <reference>
    <citation>Farley JE, Ross T, Stamper P, Baucom S, Larson E, Carroll KC. Prevalence, risk factors, and molecular epidemiology of methicillin-resistant Staphylococcus aureus among newly arrested men in Baltimore, Maryland. Am J Infect Control. 2008 Nov;36(9):644-50. doi: 10.1016/j.ajic.2008.05.005. Epub 2008 Oct 3.</citation>
    <PMID>18834755</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <results_first_submitted>February 6, 2018</results_first_submitted>
  <results_first_submitted_qc>March 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2018</results_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRSA</keyword>
  <keyword>colonization</keyword>
  <keyword>decolonization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place from January 2014-March 2015 in an outpatient HIV clinic in Baltimore, Maryland</recruitment_details>
      <pre_assignment_details>Enrolled participants were screened for Methicillin-resistant Staphylococcus aureus (MRSA). Only those with a positive MRSA swab in any body site (nares, throat, perineum, rectum, vagina) were randomized to an arm of the study to receive the decolonization protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Individual Alone</title>
          <description>Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
        </group>
        <group group_id="P2">
          <title>Individual Plus Household</title>
          <description>Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>77 enrolled participants were screened for MRSA. Only those with a positive MRSA swab in any body site (nares, throat, perineum, rectum, vagina) were randomized to an arm of the study to receive the decolonization protocol. 59 participants were not randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Individual Alone</title>
          <description>Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
        </group>
        <group group_id="B2">
          <title>Individual Plus Household</title>
          <description>Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.6" spread="4.2"/>
                    <measurement group_id="B2" value="51.4" spread="12.2"/>
                    <measurement group_id="B3" value="50.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster of Differentiation 4 (CD4) T-cell count</title>
          <description>CD4 cells per cubic millimeter of blood</description>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="676" spread="451"/>
                    <measurement group_id="B2" value="687" spread="223"/>
                    <measurement group_id="B3" value="682" spread="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV Viral Load of &lt;20 detectable copies of HIV viral load</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization</title>
        <description>Participants were decolonized with a standard Methicillin-resistant Staphylococcus aureus (MRSA) decolonization protocol and monitored for 6 months. This is the number of participants who screened positive for Methicillin-resistant Staphylococcus aureus (MRSA) 6 months after being decolonized (i.e., recurrent infection)</description>
        <time_frame>6 months</time_frame>
        <population>Only participants who received the decolonization protocol and completed the 6 month follow-up visit (7 for &quot;individual alone' and 6 for 'Individual plus household') were included in the analysis. The rest were lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Individual Alone</title>
            <description>Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
          </group>
          <group group_id="O2">
            <title>Individual Plus Household</title>
            <description>Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization</title>
          <description>Participants were decolonized with a standard Methicillin-resistant Staphylococcus aureus (MRSA) decolonization protocol and monitored for 6 months. This is the number of participants who screened positive for Methicillin-resistant Staphylococcus aureus (MRSA) 6 months after being decolonized (i.e., recurrent infection)</description>
          <population>Only participants who received the decolonization protocol and completed the 6 month follow-up visit (7 for &quot;individual alone' and 6 for 'Individual plus household') were included in the analysis. The rest were lost to follow up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to low enrollment in the intervention, statistical analysis was not possible.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The study was powered for enrollment of 100 subjects with MRSA colonization at baseline. Despite substantial screening, we were unable to enroll enough subjects to meet the necessary sample size.</non_inferiority_desc>
            <other_analysis_desc>The study was powered for enrollment of 100 subjects with MRSA colonization at baseline. Despite substantial screening, we were unable to enroll enough subjects to meet the necessary sample size.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Individual Alone</title>
          <description>Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
        </group>
        <group group_id="E2">
          <title>Individual Plus Household</title>
          <description>Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
Chlorhexidine gluconate soap: 4% chlorhexidine gluconate (soap)
Chlorhexidine gluconate oral rinse: chlorhexidine gluconate oral rinse 0.12%
Mupirocin calcium 2 % ointment: nasal mupirocin calcium 2% ointment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jason Farley</name_or_title>
      <organization>Johns Hopkins University School of Nursing</organization>
      <phone>4105027563</phone>
      <email>jfarley1@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

